Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	121
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	113
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	103
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	88
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	68
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	66
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	65
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	64
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	63
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	63
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	63
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease	56
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments	55
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis	54
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	54
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	54
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	47
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	47
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	46
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	45
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	44
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	43
The Emerging Specialty of Cardio-Rheumatology	39
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	37
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	37

Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	37
Percutaneous Coronary Interventions in Women	35
Inflammation in the Peri-ACS Period: Ready for Prime Time?	35
Myeloid Cells in Abdominal Aortic Aneurysm	35
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	34
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34
The Role of Sleep in Cardiovascular Disease	32
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	32
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	30
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	29
Low LDL-C: Is It all Good News?	29
Lipoprotein(a): from Causality to Treatment	29
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	27
Importance of Nutrition Security to CVD Prevention Efforts in the USA	26
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	25
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	25
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	24
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review	24
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	24
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	24
Update on Plant-Based Diets and Cardiometabolic Risk	24
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	23
Transgender Cardiovascular Health: Practical Management for the Clinician	23
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	22
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	22
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	21
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols	20
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	20
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	20
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	20
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	20
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	18
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	18
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	18
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications	18
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	18
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	17
Clinical Management of Dyslipidemia in Infants and Toddlers	17
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	17
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	17
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors	17
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence	17
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	17
Gene Regulatory Networks in Coronary Artery Disease	17
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	17
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	16

Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines	16
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	16
Cardiovascular Health and Disease in the Pakistani American Population	16
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	16
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	16
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	15
Bempedoic Acid: for Whom and When	15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	15
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	15
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	15
What Causes Premature Coronary Artery Disease?	15
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	15
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	15
Utility of FFRCT in Patients with Chest Pain	14
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies	14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	14
Dietary Management of Atherogenic Dyslipidemia	14
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	14
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	14
Fixed Combination for the Treatment of Dyslipidaemia	13
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	13
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	13
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	13
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	13
Circular RNA role in Atherosclerosis Development and Progression	13
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	13
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	12
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	12
Apheresis: What Should a Clinician Know?	12
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	12
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	12
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation	12
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	12
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	12
Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications	11
HDL as a Treatment Target: Should We Abandon This Idea?	11
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	11
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	11
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	11
Cardiovascular Disease Burden among African Migrants	11
Imaging Approaches to the Diagnosis of Vascular Diseases	10
S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis	10
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	10
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	10
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	10
The TICE Pathway: Mechanisms and Potential Clinical Applications	10
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	10
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	10
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	10
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	10
Obicetrapib—the Rebirth of CETP Inhibitors?	10
How to Handle Elevated Triglycerides: Life after PROMINENT	10
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	10
Gene Editing for the Treatment of Hypercholesterolemia	9
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	9
An Update on Nutrition Guidance for Cardiovascular Health	9
CETP Inhibitors: Should We Continue to Pursue This Pathway?	9
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	9
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	9
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	9
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	9
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	9
Unveiling the Sex-Based Divide: Exploring Sex Differences in Peripheral Artery Disease	9
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	8
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	8
Family Meals and Cardiometabolic Risk Factors in Young Children	8
Mechanisms Behind NAFLD: a System Genetics Perspective	8
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	8
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	8
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	8
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	8
Update on Sitosterolemia and Atherosclerosis	8
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	8
Biomarkers Differentiating Plaque Erosion from Stable Plaque	8
Health Literacy is Essential to ASCVD Prevention in Youth	8
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	8
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	8

Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing	8
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	8
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	8
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	8
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	7
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	7
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	7
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	7
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?	7
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	7
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	7
Inclisiran: How Widely and When Should We Use It?	7
Tackling the Cardio-Kidney-Metabolic Burden in Cancer	7
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	7
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	7
Familial Combined Hyperlipidemia: Myth or Reality?	7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	7
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	7
Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	7
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	7
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	7
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	6
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	6
Insight into the Mechanistic role of Colchicine in Atherosclerosis	6
Novel Therapeutics for Familial Chylomicronemia Syndrome	6
N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes	6
AI in Adipose Imaging: Revolutionizing Visceral Adipose Tissue, Ectopic Fat, and Cardiovascular Risk Assessment	6
Statin Intolerance: an Overview of US and International Guidance	6
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	6
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	6
The Role of Genetics in Advancing Cardiometabolic Drug Development	6
Telomere Length: Implications for Atherogenesis	6
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	6
Impact of Sex Differences on Lipids and Statin Utilization	6
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	6
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	6
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks	6
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	6